No Picture

Mine the Gap: More Women Embrace Mining Careers

12/08 06:07 Anonymous 0

com/articles/mine-the-gap-more-women-embrace-mining-careers-1512729000














Sammy Petrucco, second from left, swapped managing a dental practice for operating a ship loader that pours tons of iron ore onto awaiting ships in Port Hedland, Australia.Philip Gostelow for the Wall Street Journal





























Dec.

No Picture

U.S. Jobless Claims Fall

12/07 18:06 Anonymous 0

Dow Jones, a News Corp companyNews Corp is a network of leading companies in the worlds of diversified media, news, education, and information services


































































The number of claims workers made for longer than a week also dropped in the week ending Nov.25




















Dec.

No Picture

Chinese Banks Face Potential Capital Shortfall, IMF Says

12/07 18:06 Anonymous 0

Dow Jones, a News Corp companyNews Corp is a network of leading companies in the worlds of diversified media, news, education, and information services




























Some banks may not have enough assets to weather possible losses from growing credit risks, report says




















Updated Dec.ET







BEIJING—Chinese banks may have insufficient capital to weather potential losses from the nation’s rapidly mounting credit risks, the International Monetary Fund said, in a broad review of China’s financial system.

No Picture

Visa Spent a Year Developing a ‘Signature Sound’

12/07 06:07 Anonymous 0

ET










Several months ago, 10 Visa marketing employees and agency staffers met to debate the merits and nuances of sounds that could represent the Visa brand.”







From there, the team hashed out a winner: a less-than-a-second sound that signals “speed and convenience,” according to Visa.

No Picture

Roche’s Immunotherapy Drug Tecentriq Extended Patients’ Lives in Study

12/07 06:06 Anonymous 0

Roche Holding AG said Thursday that its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, offering a new hope for patients and bolstering the Swiss drugmaker’s defense against a wave of cut-price competition to its top-selling medicines.The Basel-based drugmaker said patients who received Tecentriq, along with Roche’s older cancer drug Avastin and chemotherapy, showed a 38% reduced risk of their disease worsening, compared with patients who were given.